Published in AIDS Weekly, November 10th, 2003
Investors will also receive 5-year warrants to purchase an aggregate of approximately 3 million shares of common stock at $3.32 per share.
Proceeds from the financing are expected to be used to fund the company's ongoing activities with Remune, an immune-based therapeutic vaccine being evaluated in phase II clinical studies for treatment of human immunodeficiency virus (HIV), as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.